Adrian Rawcliffe

CIK: 0001555851

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (58.3%)

Position reduction

Option Exercises (M)1 (8.3%)

Derivative conversions

Awards (A)4 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

WVE

Wave Life Sciences, Inc.

Director

ADAP

Adaptimmune Therapeutics PLC

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

WVE
Wave Life Sciences, Inc.
Oct 5, 2026
Award(A)
Direct
10.7K shares-
WVE
Wave Life Sciences, Inc.
Aug 12, 2026
Sale(S)
Direct
12.7K shares at avg. $5.29$67K
WVE
Wave Life Sciences Ltd.
Dec 8, 2025
Exercise(M)
Direct
42K shares at avg. $5.97$251K
WVE
Wave Life Sciences Ltd.
Dec 8, 2025
Sale(S)
Direct
42K shares at avg. $15.00$630K
WVE
Wave Life Sciences Ltd.
Nov 13, 2025
Sale(S)
Direct
16.1K shares at avg. $6.79$109K
WVE
Wave Life Sciences Ltd.
Aug 11, 2025
Award(A)
Direct
12.7K shares-
ADAP
Adaptimmune Therapeutics PLC
Feb 20, 2025
Award(A)
Option to purchase Ordinary Shares
Direct
3.4M shares-
ADAP
Adaptimmune Therapeutics PLC
Feb 20, 2025
Award(A)
Option to purchase Ordinary Shares
Direct
5.1M shares-
ADAP
Adaptimmune Therapeutics PLC
Jan 17, 2025
Sale(S)
Direct
30.6K shares at avg. $0.58$18K
ADAP
Adaptimmune Therapeutics PLC
Jan 15, 2025
Sale(S)
Direct
29.1K shares at avg. $0.57$17K
ADAP
Adaptimmune Therapeutics PLC
Jan 13, 2025
Sale(S)
Direct
17.9K shares at avg. $0.59$11K
ADAP
Adaptimmune Therapeutics PLC
Jan 13, 2025
Sale(S)
Direct
12.5K shares at avg. $0.59$7K

		Type	Shares	Price		Ownership
Oct 5, 2026	WVE Wave Life Sciences, Inc.	Award(A)	10,700	-	$0	Direct
Aug 12, 2026	WVE Wave Life Sciences, Inc.	Sale(S)	12,700	$5.29	$67,183	Direct
Dec 8, 2025	WVE Wave Life Sciences Ltd.	Exercise(M)	42,000	$5.97	$250,740	Direct
Dec 8, 2025	WVE Wave Life Sciences Ltd.	Sale(S)	42,000	$15.00	$630,000	Direct
Nov 13, 2025	WVE Wave Life Sciences Ltd.	Sale(S)	16,115	$6.79	$109,421	Direct
Aug 11, 2025	WVE Wave Life Sciences Ltd.	Award(A)	12,700	-	-	Direct
Feb 20, 2025	ADAP Adaptimmune Therapeutics PLC	Award(A) Option to purchase Ordinary Shares	3,428,832	-	-	Direct
Feb 20, 2025	ADAP Adaptimmune Therapeutics PLC	Award(A) Option to purchase Ordinary Shares	5,143,248	-	-	Direct
Jan 17, 2025	ADAP Adaptimmune Therapeutics PLC	Sale(S)	30,601	$0.58	$17,773	Direct
Jan 15, 2025	ADAP Adaptimmune Therapeutics PLC	Sale(S)	29,096	$0.57	$16,724	Direct
Jan 13, 2025	ADAP Adaptimmune Therapeutics PLC	Sale(S)	17,934	$0.59	$10,543	Direct
Jan 13, 2025	ADAP Adaptimmune Therapeutics PLC	Sale(S)	12,539	$0.59	$7,372	Direct

1-12 of 12 transactions

About Rawcliffe Adrian

Rawcliffe Adrian (SEC CIK 0001555851) files insider reports with the SEC as Director of Wave Life Sciences, Inc. (WVE) and Chief Executive Officer of Adaptimmune Therapeutics PLC (ADAP).

Signal8 holds 8 ownership filings by Rawcliffe Adrian, all Form 4s, filed between Jan 15, 2025 and Oct 7, 2026. Those filings report 12 transactions, from Jan 13, 2025 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rawcliffe Adrian's filings is in CAMBRIDGE, MA.

Recent filings by Rawcliffe Adrian

Oct 5, 2026: Grant or award of WVE shares (Form 4, code A).
Aug 12, 2026: Open-market sale of WVE shares (Form 4, code S).
Dec 8, 2025: Option exercise of WVE shares (Form 4, code M).
Dec 8, 2025: Open-market sale of WVE shares (Form 4, code S).
Nov 13, 2025: Open-market sale of WVE shares (Form 4, code S).

Other insiders filing for Wave Life Sciences, Inc. (WVE)

RA CAPITAL MANAGEMENT, L.P., Director
Verdine Gregory L., Director
Tan Aik Na, Director
TAKANASHI KEN, Director
CORRIGAN MARK, Director
Wagner Heidi L, Director

How to read Form 4 transaction codes